After many rocky years where it looked as though Immunocore might never realize its early promise, the UK biotech company is back on track, and expected to complete a $100m IPO within days.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?